News

Pharmabiz10h
Reckitt focus on health and hygiene initiatives helps winning Global Health Awards 2025 at House of Commons, London
Reckitt focus on health and hygiene initiatives helps winning Global Health Awards 2025 at House of Commons, London: Our ...
Pharmabiz7h
Genomill Health’s Bridge Capture technology detects key mutations from blood samples in metastatic colorectal cancer patients
Genomill Health’s Bridge Capture technology detects key mutations from blood samples in metastatic colorectal cancer patients: Turku, Finland Wednesday, July 16, 2025, 18:00 Hrs ...
Pharmabiz12h
US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%
US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%: Berlin Wednesday, July 16, 2025, 13:00 H ...
Pharmabiz8h
Merck to initiate EXPrESSIVE phase 3 trials of MK-8527, an investigational once-monthly HIV prevention pill
Rahway, New Jersey Wednesday, July 16, 2025, 17:30 Hrs [IST] ...
Pharmabiz10h
Imugene announces phase 1b trial evaluating azer-cel in patients with relapsed/refractory diffuse large B-cell lymphoma
Imugene announces phase 1b trial evaluating azer-cel in patients with relapsed/refractory diffuse large B-cell lymphoma: Sydney Wednesday, July 16, 2025, 15:30 Hrs [IST] Imugene L ...
Pharmabiz11h
GSK announces US FDA accepts application to review expanded use of RSV vaccine, Arexvy for adults 18-49 at increased risk
GSK announces US FDA accepts application to review expanded use of RSV vaccine, Arexvy for adults 18-49 at increased risk: London, UK Wednesday, July 16, 2025, 14:00 Hrs [IST] GSK ...
Pharmabiz10h
Synendos Therapeutics appoints Dr. George Garibaldi to move phase 2 clinical development of its lead drug asset SYT-510
Synendos Therapeutics appoints Dr. George Garibaldi to move phase 2 clinical development of its lead drug asset SYT-510: Basel, Switzerland Wednesday, July 16, 2025, 15:45 Hrs [IS ...
Pharmabiz11h
Nanoscope Therapeutics begins rolling submission of BLA to US FDA for gene-agnostic therapy, MCO-010 to treat retinitis pigmentosa
Nanoscope Therapeutics begins rolling submission of BLA to US FDA for gene-agnostic therapy, MCO-010 to treat retinitis pigmentosa: Dallas, Texas Wednesday, July 16, 2025, 14:30 H ...
Pharmabiz10h
Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension
Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...
Pharmabiz9h
Takeda announces positive results from two pivotal phase 3 studies of oveporexton in narcolepsy type 1
Takeda announces positive results from two pivotal phase 3 studies of oveporexton in narcolepsy type 1: Osaka Wednesday, July 16, 2025, 16:30 Hrs [IST] Takeda, a global company fo ...
Pharmabiz9h
Lupin introduces loteprednol etabonate ophthalmic suspension, 0.5% in US
Lupin introduces loteprednol etabonate ophthalmic suspension, 0.5% in US: Our Bureau, Mumbai Wednesday, July 16, 2025, 16:20 Hrs [IST] Global pharma major Lupin Limited (Lupin) an ...
Pharmabiz14h
Anthem Biosciences Rs. 3,395 crore IPO fully subscribed on day 2 of offering on July 15
Anthem Biosciences Rs. 3,395 crore IPO fully subscribed on day 2 of offering on July 15: Our Bureau, Bengaluru Wednesday, July 16, 2025, 11:30 Hrs [IST] The initial public offerin ...